Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital.

Morten LadekarlAnne Krogh NøhrMads SønderkærSimon Christian DahlLone SundeCharles VestereghemChristophe Kamungu MapendanoCharlotte Aaquist HaslundAnja PaghAndreas CarusTamás LörinczKinga Nowicka-MatusLaurids Ø PoulsenRené Johannes LaursenKaren DybkærBirgitte Klindt PoulsenJens Brøndum FrøkjærAnja Høegh BrügmannAnja ErnstAlkwin WandersMartin BøgstedInge Søkilde Pedersen

Published in: Acta oncologica (Stockholm, Sweden) (2023)

Precision medicine in end-stage cancer patients is feasible in a regional academic hospital but should continue within the frame of clinical protocols as few patients benefit. Close collaboration with comprehensive cancer centers ensures expert evaluations and equality in access to early clinical trials and modern treatment.

Keyphrases

clinical trial
healthcare
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
adverse drug
peritoneal dialysis
papillary thyroid
acute care
mental health
randomized controlled trial
patient reported outcomes
squamous cell
childhood cancer